- Facing pharmacy trends for the remainder of the year
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- Crossmark names Janet Carter-Smith VP
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
- Roxane Labs' generic prostate drug gets tentative approval from FDA
WOODCLIFF LAKE, N.J. — Generic drug maker Par Pharmaceutical has begun shipping its version of a treatment for heart rhythm problems, the company said Monday.
Par announced the shipment of propafenone SR capsules, a treatment for atrial fibrillation in patients without structural heart disease.
The drug is a generic version of GlaxoSmithKline’s Rhythmol SR, which has annual sales of around $121 million, according to IMS Health.
As the first company to file for approval of a generic version of the drug, Par has 180 days in which to market its version in direct competition with GlaxoSmithKline’s under the terms of the Hatch-Waxman Act of 1984.